Vaxcyte (PCVX) Price & Analysis

Compare

420 Followers

PCVX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$27.66 - $118.62

Previous CloseN/A

Volume105.48K

Average Volume (3M)1.81M

Market Cap

$4.94B

Enterprise Value$2.85B

Total Cash (Recent Filing)$1.66B

Total Debt (Recent Filing)$85.84M

Price to Earnings (P/E)―

Beta1.57

Next Earnings

Nov 10, 2025

EPS Estimate

-1.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.22

Shares Outstanding129,823,350

10 Day Avg. Volume2,211,436

30 Day Avg. Volume1,807,294

Financial Highlights & Ratios

PEG Ratio2.62

Price to Book (P/B)3.02

Price to Sales (P/S)0.00

P/FCF Ratio-21.02

Enterprise Value/Market Cap0.58

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-299.92

Enterprise Value/Ebitda-5.37

Forecast

1Y Price Target

$101.38

Price Target Upside152.63% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Business StrategyPCVX provided positive business updates, including taking steps to increase the odds of delivering compelling VAX-31 Ph2 infant results by adding a new optimized dose.

Financial HealthAs of June 30, 2025, the company held $2.8B in cash, cash equivalents, and investments, which management now expects to fund operations through mid-2028.

Bears Say

Timeline ExtensionsPCVX will trade down in reaction to the extended timelines.

Trial DelaysThe addition of a new optimized dose to the VAX-31 infant Ph2 should benefit efficacy but will delay the trial completion to 'by the end of 1H27.'

Vaxcyte News

Vaxcyte to establish fill-finish manufacturing in North Carolina

Vaxcyte (PCVX) announced a new agreement with Thermo Fisher Scientific (TMO) to bring additional fill-finish commercial manufacturing for...

4d ago

TMO

PCVX

Vaxcyte initiated with a Neutral at Goldman Sachs

Goldman Sachs initiated coverage of Vaxcyte (PCVX) with a Neutral rating and $38 price target The firm believes...

22d ago

PCVX

Vaxcyte Signs 15-Year Agreement with Patheon

An update from Vaxcyte ( ($PCVX) ) is now available. On September 24, 2025, Vaxcyte, Inc. entered into...

4d ago

PCVX

Vaxcyte advances VAX-31 infant Phase 2 study

Vaxcyte (PCVX) announced advancement of the modified VAX-31 infant Phase 2 randomized, dose-finding study to the third and...

1M ago

PCVX

Vaxcyte Reports Progress in Vaccine Development

Vaxcyte, Inc. ( ($PCVX) ) has released its Q2 earnings. Here is a breakdown of the information Vaxcyte,...

2M ago

PCVX

Vaxcyte’s Strategic Advancements and Financial Stability Justify Buy Rating

Leerink Partners analyst David Risinger has maintained their bullish stance on PCVX stock, giving a Buy rating yesterday....

2M ago

PCVX

Vaxcyte price target lowered to $50 from $85 at TD Cowen

TD Cowen analyst Tara Bancroft lowered the firm’s price target on Vaxcyte (PCVX) to $50 from $85 and...

2M ago

PCVX

Vaxcyte’s Strategic Adjustments and Optimized Trials Drive Buy Rating

Joseph Stringer, an analyst from Needham, reiterated the Buy rating on Vaxcyte. The associated price target remains the...

2M ago

PCVX

Promising Prospects for Vaxcyte’s VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Vaxcyte, with a...

2M ago

PCVX

Vaxcyte reports Q2 EPS ($1.22), consensus ($1.16)

“We are laser-focused on advancing the development of VAX-31 in both adults and infants, given its potential to...

2M ago

PCVX

Vaxcyte vaccine candidates contain aluminum, says Mizuho

Mizuho analyst Salim Syed comments on Outperform-rated Vaxcyte (PCVX) following reports that Health and Human Services Secretary Kennedy...

4M ago

PCVX

Vaxcyte Holds Annual Stockholders Meeting on Governance

The latest announcement is out from Vaxcyte ( ($PCVX) ). On June 12, 2025, Vaxcyte, Inc. held its...

4M ago

PCVX

FDA head says vaccine framework being prepared

FDA Commissioner Marty Makary said today at the Food and Drug Law Institute’s annual conference: “We want to...

5M ago

GSK

PFE

Vaxcyte, Inc. Reports Q1 2025 Financial Results

Vaxcyte, Inc. ( ($PCVX) ) has released its Q1 earnings. Here is a breakdown of the information Vaxcyte,...

5M ago

PCVX

PCVX FAQ

What was Vaxcyte, Inc.’s price range in the past 12 months?

Vaxcyte, Inc. lowest stock price was $27.66 and its highest was $118.62 in the past 12 months.

What is Vaxcyte, Inc.’s market cap?

Vaxcyte, Inc.’s market cap is $4.94B.

When is Vaxcyte, Inc.’s upcoming earnings report date?

Vaxcyte, Inc.’s upcoming earnings report date is Nov 10, 2025 which is in 37 days.

How were Vaxcyte, Inc.’s earnings last quarter?

Vaxcyte, Inc. released its earnings results on Aug 06, 2025. The company reported -$1.22 earnings per share for the quarter, missing the consensus estimate of -$1.16 by -$0.06.

Is Vaxcyte, Inc. overvalued?

According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vaxcyte, Inc. pay dividends?

Vaxcyte, Inc. does not currently pay dividends.

What is Vaxcyte, Inc.’s EPS estimate?

Vaxcyte, Inc.’s EPS estimate is -1.24.

How many shares outstanding does Vaxcyte, Inc. have?

Vaxcyte, Inc. has 129,823,350 shares outstanding.

What happened to Vaxcyte, Inc.’s price movement after its last earnings report?

Vaxcyte, Inc. reported an EPS of -$1.22 in its last earnings report, missing expectations of -$1.16. Following the earnings report the stock price went down -9.061%.

Which hedge fund is a major shareholder of Vaxcyte, Inc.?

Currently, no hedge funds are holding shares in PCVX

Vaxcyte Stock Smart Score

Underperform

Fundamentals

Return on Equity

-21.65%

Trailing 12-Months

Asset Growth

58.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vaxcyte, Inc.

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing innovative vaccines for the prevention of infectious diseases. Operating within the pharmaceutical and biotechnology sectors, Vaxcyte's core product offerings include conjugate and protein-based vaccines designed to address significant unmet medical needs. The company's lead vaccine candidates aim to provide comprehensive protection against pneumococcal infections and other bacterial pathogens.

Vaxcyte (PCVX) Earnings & Revenues

Historic Earnings Reports

PCVX Stock 12 Month Forecast

Average Price Target

$101.38

▲(152.63% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","97":"$97","164":"$164","63.5":"$63.5","130.5":"$130.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":163,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$163.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$101.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,63.5,97,130.5,164],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.56,41.67076923076923,51.78153846153846,61.892307692307696,72.00307692307692,82.11384615384615,92.22461538461539,102.33538461538461,112.44615384615385,122.55692307692308,132.6676923076923,142.77846153846153,152.88923076923078,{"y":163,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.56,36.93076923076923,42.301538461538456,47.67230769230769,53.043076923076924,58.41384615384615,63.78461538461538,69.15538461538462,74.52615384615385,79.89692307692307,85.2676923076923,90.63846153846154,96.00923076923077,{"y":101.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.56,32.05538461538461,32.55076923076923,33.04615384615384,33.54153846153846,34.036923076923074,34.53230769230769,35.027692307692305,35.52307692307692,36.01846153846154,36.51384615384615,37.00923076923077,37.504615384615384,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":78.59,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.76,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.54,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.02,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >